Bhasin S, Heber D, Steiner B S, Handelsman D J, Swerdloff R S
J Clin Endocrinol Metab. 1985 May;60(5):998-1003. doi: 10.1210/jcem-60-5-998.
Chronic treatment with agonist analogs of GnRH results in reversible oligospermia in man, but leads to impotence and decreased libido due to a concomitant fall in serum testosterone (T) concentrations. We, therefore, assessed the effects of combined treatment with a potent GnRH agonist and T on gonadotropins and spermatogenesis in normal men, anticipating that addition of androgen would prevent agonist-induced changes in libido. Seven normal men were treated with 200 micrograms of the GnRH agonist D-(Nal2)6GnRH (GnRH-A), sc, daily for 16 weeks. In addition, 200 mg T enanthate were administered every 2 weeks for the entire 16-week treatment period. Basal LH, FSH, and T concentrations were measured every week during a 5-week control period, daily on treatment days 0, 1-10, 14, 18, 22, 26, and 28, every week thereafter until day 56, and every 2 weeks thereafter for the remainder of the treatment and recovery phases. Detailed analysis of LH and FSH over the 24-h period was performed by multiple blood sampling on days 0, 1, 10, 28, 56, 84, and 112. Semen analyses were performed every week during the control phase and every 2 weeks during the treatment and recovery phases. The mean sperm count declined by 83%, to a nadir of 16.6 +/- 6.2 (+/- SEM) million/ml. One subject had no significant decrease in sperm count. Azoospermia was not achieved in any subject. Basal serum LH concentrations, after an early phase of stimulation, declined to near baseline by day 14. However, basal, 24-h integrated serum LH concentrations, and 24-h urinary LH excretion were not significantly lowered by combined treatment. Bioassayable serum LH concentrations, however, declined significantly from 20.4 +/- 6.3 to 4.5 +/- 0.5 mIU/ml, and the bioassayable to immunoassayable LH ratio decreased from 2.1 +/- 1.0 to 0.7 +/- 0.1 after 16 weeks of GnRH-A treatment. Basal and 24-h integrated FSH concentrations, after an initial period of stimulation, declined progressively to baseline by days 5-6 and were significantly below baseline by day 112. Serum T concentrations did not fall into the hypogonadal (less than 250 ng/dl) range in any subject at any time during the treatment period. After discontinuation of treatment, LH, FSH, and sperm counts returned to normal in all subjects. Thus, single daily injection of GnRH-A and T failed to predictably induce azoospermia in normal men over the 16-week treatment period.(ABSTRACT TRUNCATED AT 400 WORDS)
长期使用促性腺激素释放激素(GnRH)激动剂类似物治疗可导致男性可逆性少精子症,但由于血清睾酮(T)浓度同时下降,会导致阳痿和性欲减退。因此,我们评估了强效GnRH激动剂与T联合治疗对正常男性促性腺激素和精子发生的影响,预计添加雄激素可预防激动剂引起的性欲变化。7名正常男性每天皮下注射200微克GnRH激动剂D-(Nal2)6GnRH(GnRH-A),持续16周。此外,在整个16周的治疗期间,每2周注射200毫克庚酸睾酮。在为期5周的对照期内每周测量基础促黄体生成素(LH)、促卵泡生成素(FSH)和T浓度,在治疗第0、1 - 10、14、18、22、26和28天每天测量,此后每周测量直至第56天,在治疗和恢复阶段的剩余时间每2周测量一次。在第0、1、10、28、56、84和112天通过多次采血对24小时内的LH和FSH进行详细分析。在对照期每周进行精液分析,在治疗和恢复阶段每2周进行一次。平均精子计数下降了83%,最低点为16.6±6.2(±标准误)百万/毫升。一名受试者的精子计数没有显著下降。所有受试者均未达到无精子症。基础血清LH浓度在早期刺激阶段后,到第14天降至接近基线水平。然而,联合治疗并未显著降低基础、24小时综合血清LH浓度以及24小时尿LH排泄量。然而,生物活性血清LH浓度从20.4±6.3显著降至4.5±0.5毫国际单位/毫升,GnRH-A治疗16周后,生物活性与免疫活性LH比值从2.1±1.0降至0.7±0.1。基础和24小时综合FSH浓度在初始刺激期后,在第5 - 6天逐渐降至基线水平,并在第112天显著低于基线水平。在治疗期间的任何时候,所有受试者的血清T浓度均未降至性腺功能减退(低于250纳克/分升)范围。治疗中断后,所有受试者的LH、FSH和精子计数均恢复正常。因此,在16周的治疗期内,每日单次注射GnRH-A和T未能在正常男性中可预测地诱导无精子症。(摘要截短至400字)